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ABSTRACT
Dysregulated NF-κB signaling is critical for lymphomagenesis. The regulation, 
function, and clinical relevance of c-Rel/NF-κB activation in diffuse large B-cell 
lymphoma (DLBCL) have not been well studied. In this study we analyzed the  
prognostic significance and gene-expression signature of c-Rel nuclear expression 
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as surrogate of c-Rel activation in 460 patients with de novo DLBCL. Nuclear c-Rel 
expression, observed in 137 (26.3%) DLBCL patients frequently associated with 
extranoal origin, did not show significantly prognostic impact in the overall- or 
germinal center B-like-DLBCL cohort, likely due to decreased pAKT and Myc levels, 
up-regulation of FOXP3, FOXO3, MEG3 and other tumor suppressors coincided 
with c-Rel nuclear expression, as well as the complicated relationships between  
NF-κB members and their overlapping function. However, c-Rel nuclear expression 
correlated with significantly poorer survival in p63+ and BCL-2− activated  
B-cell-like-DLBCL, and in DLBCL patients with TP53 mutations. Multivariate analysis 
indicated that after adjusting clinical parameters, c-Rel positivity was a significantly 
adverse prognostic factor in DLBCL patients with wild type TP53. Gene expression 
profiling suggested dysregulations of cell cycle, metabolism, adhesion, and migration 
associated with c-Rel activation. In contrast, REL amplification did not correlate 
with c-Rel nuclear expression and patient survival, likely due to co-amplification of 
genes that negatively regulate NF-κB activation. These insights into the expression, 
prognostic impact, regulation and function of c-Rel as well as its crosstalk with the 
p53 pathway underscore the importance of c-Rel and have significant therapeutic  
implications.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is a 
heterogeneous aggressive non-Hodgkin lymphoma that 
can be classified into germinal center B-like (GCB) or 
activated B-cell-like (ABC) DLBCL. Aberrant activation 
of nuclear factor-kappaB (NF-κB), either through the 
“canonical” pathway activating p50/p65 and p50/c-
Rel dimers, or through the “non-canonical” pathway 
activating p52/RelB dimers, has been associated with 
tumor proliferation and survival in DLBCL, especially in 
the ABC subtype [1, 2]. The canonical and non-canonical 
pathways are generally believed to be independent; 
however, the non-canonical pathway may attenuate 
activities of the canonical pathways [3].
c-Rel encoded by the REL gene is a unique 
NF-κB member, predominantly expressed in lymphoid 
and myeloid tissues, likely contributed by the unique 
regulators for c-Rel activation. NF-κB inhibitor IκBα 
preferentially inhibits p65/p50 dimers, whereas IκBε 
controls p65/c-Rel, and c-Rel activation also depends on 
the non-redundant regulator IκBβ [4–7], and the protease 
activities of MALT1 [8]. MALT1 inhibitors specifically 
impair c-Rel nuclear localization and display selective 
activity against ABC-DLBCL ex vivo [9]. In addition, 
novel IκB kinase (IKK)-dependent and proteasomal-
independent pathway was found to degrade IκBα and 
activate p50/c-Rel in B-cells [10], triggered by stimuli 
different from the non-canonical NF-κB pathway. 
However, little is known about whether and how the 
upstream stimuli for NF-κB activation, e.g., signaling 
through B-cell receptors (BCR), T-cell receptors (TCR), 
tumor-necrosis factor  (TNF) receptors, Toll-like 
receptors (TLR), and mitogen-activated protein kinases 
(MAPK) [11], differentially regulate c-Rel and other 
NF-κB subunits.
c-Rel has both nonredundant and overlapping 
functions compared with p65 and p50. c-Rel regulates 
cytokine production and plays an important role in 
proliferation and inflammation mainly regulating 
development of T-cells [12–14]. c-Rel promotes cell 
survival by transactivating antiapoptotic and cell cycle 
genes, such as BCLXL/BCL2L1, BCL2A1, XIAP, cIAP, 
and cyclins [4, 15, 16]. In addition, during GC reaction 
in B-cell development, c-Rel is required for B-cell 
activation before GC formation and maintenance of 
the GC reaction by regulating metabolism, fueling 
proliferation independent of Myc [17], and is crucial 
for the development of follicular helper T cells [7, 18]. 
c-Rel-knockout mice are viable but have deficiencies 
in immune responses [4, 19]. However, c-Rel, but not 
other NF-κB members, has a unique ability to transform 
avian lymphoid cells in vitro [4], and is associated with 
increased lymphoma risk in vivo [20].
c-Rel functions are also affected by the p53 
pathway. In mouse models the requirement for NF-κB 
signaling in tumor development depends on the p53 
status [21]. Wild-type (WT-) p53 and NF-κB antagonize 
each other, however NF-κB can also enhance p53 stability 
and activities in some circumstances [22]. In contrast, 
p53 mutants (MUT-p53) cooperate with NF-κB to 
promote tumor invasion and metastasis [23, 24]. p53 can 
also directly regulate NF-κB expression and activation. 
WT-p53 negatively regulates NF-κB activation and 
function [25, 26], whereas MUT-p53 induces p52/NFKB2 
gene expression [27]. Moreover, crosstalk also exists 
between NF-κB and p63, another member of the p53 
family [28–30]. Overexpression of ΔNp63α leads to 
increased c-Rel expression, and epidermal hyperplasia 
and diffuse inflammation in transgenic mice [28]. The 
ΔNp63α–c-Rel complex represses CDKN1A/p21 and 
promotes epithelial cell proliferation in human squamous 
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carcinoma cells [29]. In head and neck squamous cell 
carcinoma with MUT-p53, c-Rel overexpression 
activated by TNF-α modulates ΔNp63α/ Tap73 
interactions and their function, promoting proliferation 
and cell survival [30].
c-Rel has been proposed to be an attractive 
therapeutic target, whose inhibition can suppress tumor 
growth without causing systemic tissue toxicity [19]. 
A study group showed that c-Rel inhibition is a novel 
strategy to ameliorate GVHD reduced alloactivation 
without compromising T-cell mediated immune 
responses [31], and a small molecule c-Rel inhibitor 
had anti-proliferative effect in both GCB- and ABC-
DLBCL cell lines [32]. Since REL gene was found 
frequently amplified in DLBCL (~15%), REL activation 
may play a role in lymphomagenesis, which however, 
was not supported by immunofluorescence analysis [33]. 
One study of 68 de novo DLBCL cases found that 15 GCB-
DLBCL cases positive for c-Rel nuclear expression by 
immunohistochemistry had worse survival compared to 9 
GCB-DLBCL cases negative for c-Rel nuclear expression 
(P = 0.045) [34]. In contrast, another study using a > 30% 
cutoff for c-Rel nuclear staining showed that 57 c-Rel+ 
DLBCL patients had significantly better overall survival 
than 31 c-Rel− DLBCL patients [35]. Large scale studies 
of REL amplification and c-Rel nuclear expression, and the 
prognostic impact of concurrent dysregulation of NF-κB 
and TP53 [36] in DLBCL are lacking. In this study, we 
aimed to evaluate the clinical significance of c-Rel 
nuclear expression and REL amplification in DLBCL 
patients, to gain insight into the underlying biology, c-Rel 
function, activation mechanisms, and relationship with 
other NF-κB subunits.
RESULTS
c-Rel nuclear expression and correlation with 
nuclear expression of other NF-κB subunits
Immunohistochemistry was used to analyze the 
nuclear expression of c-Rel, as the surrogate marker 
for c-Rel activation [34] (Fig. 1A). A cutoff of ≥5% of 
tumor cells with positive c-Rel staining nuclei was used to 
identify positive c-Rel nuclear expression (c-Rel+). Using 
this cutoff, 137 patients (26.3%) of the 460 successfully 
stained cases had c-Rel+ DLBCL, with different expression 
levels (5–90% of the tumor cells with c-Rel+ nuclei), 
whereas majority (73.7%) of the cases were negative for 
c-Rel nuclear expression with or without cytoplasmic 
staining (Fig. 1B, Supplementary Fig. S1A). The mean 
expression level of nuclear c-Rel was significantly 
lower than those of nuclear p65 and p50 in our cohort 
(Supplementary Fig. S1B).
Nuclear c-Rel positivity did not correlate with 
REL mRNA levels by Spearman rank correlation 
(r = 0.004, P = 0.94), either in GCB- or ABC-
DLBCL (Fig. 1C). Consistent with a previous study 
[35], GCB- and ABC-DLBCL had similar level of 
nuclear c-Rel protein expression (Fig. 1D). However, 
REL mRNA was significantly higher in the GCB subtype 
(P < 0.0001), even after exclusion of cases with REL 
amplification or potential gains due to polysomies 
(Supplementary Fig. S1C).
Nuclear expression levels of c-Rel correlated 
positively with expression of other NF-κB subunits 
(significant for p52 and RelB by Spearman rank correla-
tion): p50 (r = 0.12, P = 0.12), p52 (r = 0.26, P = 0.724E-8), 
 p65 (r = 0.085, P = 0.073), and RelB (r = 0.12, 
P = 0.013). c-Rel+ correlated with significantly higher 
levels of nuclear p65 and p52 in GCB-DLBCL, and 
p50, p52 and RelB in ABC-DLBCL (Fig. 1E-H). At 
the mRNA level, c-Rel+ correlated with upregulation of 
NFKB1 and RELA (but not NFKB2 or RELB) in ABC-
DLBCL (Supplementary Fig. S1D-E). It has been known 
that c-Rel predominately forms dimers with p50 [1]. 
Our coimmunoprecipitation analysis using nuclear 
extracts purified from representative human derived 
GCB- and ABC-DLBCL cell lines (MS, DB, LR, LP) 
however showed that c-Rel predominantly binds to p65 in 
all cell lines (more intense in GCB than ABC cell lines); 
and that in some cell lines, p52 and RelB also formed 
dimers with c-Rel but to a lesser extent (Fig. 1I).
Prognostic impact of c-Rel nuclear expression
Clinicopathologic features
The clinicopathologic features of the study cohort 
are shown in Table 1. Interestingly, the c-Rel+ DLBCL 
group had a higher proportion of patients with extranodal 
disease (P = 0.0033), and had no association with other 
clinical parameters. Pathologically, the c-Rel+ compared 
to the c-Rel− DLBCL group less frequently had Myc or 
pAKT overexpression, whereas more frequently expressed 
nuclear p50, p52 and RelB (Table 1).
Moreover, dividing into GCB and ABC subtypes, 
c-Rel+ GCB-DLBCL was associated with female sex, 
low ECOG performance status score, and less MYC 
translocations compared with c-Rel− GCB-DLBCL, 
whereas in the ABC subtype, c-Rel+ ABC-DLBCL was 
associated with extranodal disease (Table 1).
Univariate survival analysis in various DLBCL 
molecular subsets
c-Rel nuclear expression did not correlate with 
patient survival in the overall- or GCB-DLBCL, whereas 
c-Rel+ ABC-DLBCL tended to have a poorer survival 
(Fig. 2A-2C). However, in DLBCL especially in ABC-
DLBCL with low Bcl-2 (<70%), c-Rel+ correlated 
significantly with poorer survival (Fig. 2D). In an effort 
to identify the functionally relevant c-Rel dimers, we 
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examined the prognostic impact of c-Rel+ within the 
following DLBCL subsets: p50−, p65−, p52−, RelB−, p50+, 
p65+, p52+ and RelB+. c-Rel+ DLBCL showed trends 
toward poorer survival only within the p50+ and p65+ 
subsets but not in other subsets (Fig. 2E-2F).
c-Rel nuclear expression did not correlate with 
survival in DLBCL patients with WT-p53 (however, 
the c-Rel+ compared with the c-Rel− group had a small 
proportion of patients with stage III/IV disease, Table 2). 
In contrast, among DLBCL patients with MUT-p53, 
c-Rel+ correlated with significantly worse survival 
(Fig. 2G-2H). The prognostic impact of c-Rel positivity 
in the p65−, p65+, p50− and p50+ subsets with WT-p53 or 
MUT-p53 was shown in Supplementary Figure S2A-2H. 
Among all the DLBCL patients, c-Rel nuclear expression 
concurrent with TP53 mutations significantly predicted 
poorer survival (Fig. 2I). Moreover, p63 appears to be 
another tumor suppressor beside WT-p53 in suppressing 
the adverse impact of c-Rel activation, suggested by 
the correlation of p63 expression with better survival 
in c-Rel+ ABC-DLBCL (Fig. 2J), and a similar trend in 
GCB-DLBCL patients (P = 0.18). However, the favorable 
correlation of p63 expression in c-Rel+ ABC-DLBCL 
was abrogated by TP53 mutations (Supplementary 
Fig. S2K). Conversely, c-Rel conferred significantly 
poorer survival in p63− but not in p63+ ABC-DLBCL 
(Fig. 2K-L). In patients with p63+ ABC-DLBCL, c-Rel 
conferred significantly poorer survival when concurrent 
with TP53 mutations (Supplementary Fig. S2K).
Multivariate survival analysis in overall-, GCB- and 
ABC-DLBCL and in the WT-/MUT-p53 subsets
Multivariate survival analysis adjusting clinical 
parameters only (IPI alone or using individual five IPI 
components, sex, B-symptoms, and tumor size) indicated 
that c-Rel+ was not an independent prognostic factor. 
However, when the potentially compounding biomarkers 
(Myc+, Bcl-2+, and TP53 mutations, Table 1) were also 
included in the multivariate analysis, c-Rel+ showed 
significant prognostic value for poorer overall survival in 
the whole and ABC-DLBCL cohorts. c-Rel+ also predicted 
poorer progression-free survival in ABC-DLBCL with 
a borderline P value (Table 3). c-Rel+ did not predict 
survival in GCB-DLBCL.
Figure 1: Nuclear expression of c-Rel and other NF-κB subunits. A-B. Representative immunohistochemical staining for 
positive and negative nuclear c-Rel expression. C. Nuclear c-Rel positivity did not correlate with REL mRNA levels in GCB- and ABC-
DLBCL. D. Expression levels of nuclear c-Rel did not show significant difference between GCB- and ABC-DLBCL. E-H. Association 
of c-Rel positivity with nuclear expression of other NF-κB subunits. Note: red lines indicate upregulation whereas blue lines indicated 
downregulation with significant or border-line P values. I. Dimerization of NF-κB subunits in DLBCL in vitro. Nuclear extract purified 
from MS and DB (GCB), and LR and LP (ABC) cells were subjected to coimmunoprecipitation analysis with p65, c-Rel, p52, and RelB 
antibodies. Normal rabbit IgG was used as a nonspecific negative control. Precipitated immune-complexes were subjected to Western blot 
analysis with p65, c-Rel, p52, and RelB antibodies.
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Table 1: Clinicopathologic characteristics of 460 de novo DLBCL patients treated with R-CHOP
DLBCL GCB-DLBCL ABC-DLBCL
c-Rel+ c-Rel− c-Rel+ c-Rel− c-Rel+ c-Rel−
Variables  N (%) N (%) P N (%) N (%) P N (%) N (%) P
Patients 137 (100) 323 (100) 66 (100) 165 (100) 70 (100) 158 (100) .68
Gender
Male 78 (57) 192 (59) .61 31 (47) 104 (63) .025 46 (66) 88 (56) .16
Female 59 (43) 131 (41) 35 (53) 61 (37) 24 (34) 70 (44)
Age (yr)
<60 52 (38) 140 (43) .30 29 (44) 86 (52) .31 22 (31) 54 (34) .76
≥60 85 (62) 183 (57) 37 (56) 79 (48) 48 (69) 104 (66)
Stage
I-II 65 (50) 143 (46) .39 36 (57) 84 (53) .56 28 (42) 59 (38) .54
III-IV 65 (50) 171 (54) 27 (43) 75 (47) 38 (58) 96 (62)
B-symptoms
No 88 (71) 196 (63) .099 46 (79) 108 (68) .09 42 (65) 88 (58) .33
Yes 36 (29) 117 (37) 12 (21) 52 (32) 23 (35) 65 (42)
LDH
Normal 46 (40) 113 (37) .56 24 (44) 57 (37) .37 22 (37) 56 (37) .98
Elevated 69 (60) 193 (63) 31 (56) 98 (63) 37 (63) 95 (63)
# of extranodal sites
0–1 103 (80) 235 (75) .31 49 (80) 121 (77) .55 54 (81) 114 (74) .29
≥2 26 (20) 77 (25) 12 (20) 37 (23) 13 (19) 40 (26)
Performance status
0–1 95 (86) 247 (83) .47 48 (94) 125 (83) .055 46 (78) 122 (82) .52
≥2 16 (14) 52 (17) 3 (6) 25 (17) 13 (22) 27 (18)
Size of largest tumor
<5cm 47 (53) 149 (58) .38 22 (51) 78 (61) .24 25 (54) 71 (55) .94
≥5cm 42 (47) 107 (42) 21 (49) 49 (39) 21 (46) 58 (45)
IPI risk group
0–2 83 (65) 189 (60) .32 46 (75) 104 (65) .14 36 (54) 85 (54) .99
3–5 45 (35) 127 (40) 15 (25) 56 (35) 30 (46) 71 (46)
Therapy response
CR 103 (75) 247 (77) .77 51 (77) 121 (73) .54 51 (73) 126 (80) .25
PR 17 42 7 20 10 22
SD 6 13 4 8 2 5
PD 11 21 4 16 7 5
Primary origin
Nodal 70 (53) 222 (69) .0015 36 (57) 113 (69) .095 34 (51) 109 (69) .0077
Extranodal 61 (47) 99 (31) 27 (43) 51 (31) 33 (49) 48 (31)
(Continued )
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Interestingly, in the WT-p53 subset, multivariate 
survival analysis adjusting clinical parameters indicated 
that c-Rel+ was an independent adverse prognostic factor 
(Table 3). Dividing into GCB and ABC subcohorts, the 
P values for the prognostic significance of c-Rel positivity 
remained significant for OS in both GCB- and ABC-DLBCL 
with WT-p53 after adjusting all the clinical parameters 
(P = 0.025 and P = 0.019 respectively), and for PFS in ABC-
DLBCL with WT-p53 (P = 0.04). In the MUT-p53 subset, on 
the contrary, multivariate survival analysis adjusting clinical 
parameters suggested that the predictive value of c-Rel+ for 
poorer survival was not significant.
DLBCL GCB-DLBCL ABC-DLBCL
c-Rel+ c-Rel− c-Rel+ c-Rel− c-Rel+ c-Rel−
Variables  N (%) N (%) P N (%) N (%) P N (%) N (%) P
Ki-67
<70% 49 (36) 113 (35) 1.0 27 (41) 64 (39) .88 22 (31) 49 (31) 1.0
≥70% 88 (64) 207 (65) 39 (59) 98 (61) 48 (69) 109 (69)
TP53 mutation
WT TP53 91 (74) 222 (78) .45 42 (71) 107 (72) 1.0 49 (77) 115 (84) .24
MUT TP53 32 (26) 64 (22) 17 (29) 42 (28) 15 (23) 22 (16)
MYC translocation
− 93 (91) 180 (86) .27 44 (94) 77 (78) .0019 49 (89) 103 (94) .36
+ 9 (9) 29 (14) 3 (6) 22 (22) 6 (11) 7 (6)
BCL2 translocation
− 103 (81) 208 (82) 1.0 43 (69) 82 (66) .63 60 (92) 126 (97) .16
+ 24 (19) 47 (18) 19 (31) 43 (34) 5 (8) 4 (3)
BCL6 translocation
− 75 (70) 144 (65) .37 43 (83) 82 (72) .14 31 (57) 62 (58) .95
+ 32 (30) 77 (35) 9 (17) 32 (28) 23 (43) 45 (42)
Nuclear p50
− 50 (37) 168 (53) .0014 32 (49) 102 (62) .076 18 (26) 66 (44) .016
+ 86 (63) 147 (47) 34 (51) 62 (38) 51 (74) 85 (56)
Nuclear p52
− 77 (57) 231 (77) <.0001 38 (59) 115 (76) .022 39 (56) 116 (79) .0007
+ 58 (43) 68 (23) 26 (41) 37 (24) 31 (44) 31 (21)
Nuclear p65
− 48 (35) 135 (43) .12 21 (32) 65 (41) .23 27 (39) 70 (45) .39
+ 89 (65) 179 (57) 45 (68) 93 (59) 43 (61) 86 (55)
Nuclear RelB
− 109 (81) 266 (88) .056 54 (83) 139 (89) .28 54 (78) 127 (87) .11
+ 26 (19) 37 (12) 11 (17) 18 (11) 15 (22) 19 (13)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell like; ABC, activated B-cell like; LDH, lactate 
dehydrogenase; IPI, international prognostic index; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive 
disease.
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Potential molecular mechanisms underlying the 
prognostic impact of c-Rel positivity
A multitude of correlation and GEP analysis were 
performed to understand the prognostic effect of c-Rel 
nuclear expression observed in our cohorts.
Decreased AKT, Myc, and p53 expression in 
c-Rel+ patients
Contrary to expectation at the protein 
level, there were inverse correlations between 
c-Rel and pAKT (r = −0.22, P = 0.0008; Fig. 3A, 
Supplementary Fig. S1F) in DLBCL, between c-Rel and 
Myc (r = −0.20, P = 2.92E-5), and between c-Rel and p53 
(WT or MUT) (r = −0.20, P = 0.005) in GCB subtype by 
Spearman rank correlation (Fig. 3B, 3D; Supplementary 
Fig. S1G-S1H). Higher c-Rel expression levels (≥30%) 
coincided with decreased Myc in both GCB- and ABC-
DLBCL (Fig. 3C). These correlations may not have 
resulted from transcriptional regulations by c-Rel, 
since c-Rel positivity did not correlate with AKT1, 
MYC (Supplementary Fig. S1I-1J) or TP53 (P = 0.34 
in GCB-DLBCL, and P = 0.088 for TP53 upregulation 
in ABC-DLBCL) mRNA expression significantly, and 
that in GCB-DLBCL cases without MYC translocations, 
c-Rel+ still correlated with decreased Myc levels in GCB-
DLBCL.
To understand the mechanisms underlying these 
inverse correlations, we compared the mRNA expression 
levels of genes known for c-Rel activation in c-Rel+ 
and c-Rel− DLBCL. We found that genes involved 
Figure 2: Prognostic significance of c-Rel nuclear expression in various DLBCL subsets. A–B. In the overall- and GCB-
DLBCL, c-Rel positivity did not correlate with patient survival. C. In ABC-DLBCL, c-Rel+ as a univariate did not correlate significantly 
with patient survival although a trend toward poorer survival was suggested. D. In Bcl-2− (<70%) ABC-DLBCL, c-Rel+ correlated with 
significantly poorer patient survival. E–F. c-Rel+ concurrent with p50 or p65 expression correlated with poorer patient survival with 
marginal P values. G–I. In DLBCL with MUT-p53 but not WT-p53, c-Rel+ correlated with significantly poorer patient survival. J. In ABC-
DLBCL with c-Rel nuclear expression, p63 expression correlated with significantly better patient survival. K–L. Only in p63− but not p63+ 
ABC-DLBCL subcohort, c-Rel positivity correlated with significantly poorer patient survival. Abbreviations: OS, overall survival; PFS, 
Progression-free survival.
Oncotarget23164www.impactjournals.com/oncotarget
Table 2: Clinicopathologic characteristics of c-Rel+ versus c-Rel− DLBCL patients with wild type 
(WT) or mutated (MUT) p53
WT-p53
c-Rel+
WT-p53
c-Rel−
MUT-p53
c-Rel+
MUT-p53
c-Rel−
Variables N (%) N (%) P N (%) N (%) P
Patients 91 (100) 222 (100) 32 (100) 64 (100) .45
Gender
Male 52 (57) 135 (61) .55 21 (66) 35 (55) .31
Female 39 (43) 87 (39) 11 (34) 29 (45)
Age (yr)
<60 34 (38) 89 (40) .70 11 (34) 27 (42) .51
≥60 57 (62) 133 (60) 21 (26) 37 (58)
Stage
I-II 46 (55) 92 (43) .067 16 (50) 29 (45) .66
III-IV 38 (45) 122 (57) 16 (50) 35 (55)
B-symptoms
No 61 (74) 138 (65) .10 21 (75) 40 (63) .24
Yes 21 (26) 76 (35) 7 (25) 24 (37)
Serum LDH
Normal 35 (49) 82 (39) .16 9 (31) 22 (36) .64
Elevated 37 (51) 127 (61) 20 (69) 39 (64)
# of extranodal sites
0–1 70 (83) 160 (75) .13 26 (84) 49 (78) .49
≥2 14 (17) 53 (25) 5 (16) 14 (22)
ECOG score
0–1 62 (87) 172 (84) .54 25 (89) 53 (88) .90
≥2 9 (13) 32 (16) 3 (11) 7 (12)
Size of largest tumor
<5cm 33 (58) 113 (61) .70 9 (39) 29 (53) .27
≥5cm 24 (42) 73 (39) 14 (61) 26 (47)
IPI risk group
0–2 58 (70) 128 (59) .082 20 (65) 37 (59) .59
3–5 25 (30) 89 (41) 11 (35) 26 (41)
Therapy response
CR 74 (81) 178 (80) .82 17 (53) 43 (67) .18
PR 10 25 5 14
SD 2 6 4 2
PD 5 13 6 5
(Continued )
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in BCR signaling, including CD79A, CD19, LYN, 
SYK, CARD11, MALT1, BLNK, BTK, and ZAP70 [2], 
and MAP3K7/TAK1 [7], were significantly upregulated in 
c-Rel+ compared with c-Rel− GCB-DLBCL. These 
genes did not show significantly differential expression 
correlating to c-Rel+ in ABC-DLBCL (Supplementary 
Fig. S3A-S3J). TNF, MAPK and TLR signaling which 
are also known as NF-κB activation mechanisms [3, 11], 
might not contribute to c-Rel activation significantly 
in our DLBCL cohort, suggested by non-significant 
correlations between c-Rel positivity and gene 
expression of CD40 (GCB, P = 0.23; ABC, P = 0.70), 
MAP3K14/NIK (GCB, P = 0.39; ABC, P = 0.29), BAFF 
(GCB, P = 0.38;  ABC, P = 0.73), TNF (GCB, P = 0.51; 
ABC, P = 0.61), TNFRSF11 (GCB, P = 0.75; ABC, 
P = 0.83), TNFSF11 (GCB, P = 0.74; ABC, P = 0.84), 
TNFRSF8 (GCB, P = 0.51; ABC, P = 0.22), TNFSF8 
(GCB, P = 0.69; ABC, P = 0.72), TRAIL (GCB, P = 0.58; 
ABC, P = 0.17), TRAF1/2/5/6 (GCB, P = 0.10, 0.89. 
0.48 and 0.43 respectively; ABC, P = 0.37, 0.66, 0.35 
and 0.83 respectively), TANK (GCB, P = 0.37; ABC, 
P = 0.44), MAP3K8 (GCB, P = 0.12; ABC, P = 0.51), 
MAP3K3 (GCB, P = 0.89; ABC, P = 0.68), TLR4 (GCB, 
P = 0.53; ABC, P = 0.06 for downregulation) and etc. 
However, TNFRSF13C (encoding BAFFR) and TLR2 
were significantly upregulated in GCB-DLBCL (P = 0.017 
and P = 0.018 respectively). Other TLRs (TLR1, 3, 5–10) 
did not show significantly differential expression between 
the c-Rel+ and c-Rel− groups.
On the other hand, A20/TNFAIP3 and TNIP1 
which terminate NF-κB signaling [37] were also 
significantly upregulated in c-Rel+ GCB-DLBCL (Fig. 3E, 
Supplementary Fig. S3K). Analyzing expression of NF-
κB regulators IKK and IκB genes showed that IKK2/
IKBKB (but not IKK1) was upregulated in c-Rel+ GCB-
DLBCL (marginal P value; Supplementary Fig. S3L), 
WT-p53
c-Rel+
WT-p53
c-Rel−
MUT-p53
c-Rel+
MUT-p53
c-Rel−
Variables N (%) N (%) P N (%) N (%) P
Ki-67
<70% 39 (43) 77 (35) .20 6 (19) 19 (30) .33
≥70% 52 (57) 143 (65) 26 (81) 44 (70)
Cell-of-origin
ABC 49 (54) 115 (52) .80 15 (47) 22 (34) .27
GCB 42 (46) 107 (48) 17 (53) 42 (66)
Nuclear p50
− 31 (34) 109 (50) .012 13 (41) 38 (61) .08
+ 59 (66) 108 (50) 19 (59) 24 (39)
Nuclear p52
− 53 (59) 157 (76) .0053 16 (50) 49 (83) .0014
+ 37 (41) 50 (24) 16 (50) 10 (17)
Nuclear p65
− 37 (41) 101 (47) .38 10 (31) 20 (32) 1.0
+ 54 (59) 115 (53) 22 (69) 42 (68)
Nuclear RelB
− 73 (81) 179 (86) .30 24 (77) 55 (93) .043
+ 17 (19) 29 (14) 7 (23) 4 (7)
MYC translocation
− 69 (93) 130 (87) .18 19 (91) 30 (83) .70
+ 5 (7) 20 (13) 2 (9) 6 (17)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; IPI, international prognostic index; CR, complete 
remission; PR, partial response; SD, stable disease; PD, progressive disease; GCB, germinal center B-like; ABC, activated B-cell-like.
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Table 3: Multivariate survival analysis of clinicopathologic parameters in DLBCLs treated with 
R-CHOP
OS PFS
Variables HR 95% CI P HR 95% CI P
Overall DLBCL
B-symptoms 1.54 1.06–2.23 .024 1.40 .97–2.01 .07
IPI >2 2.25 1.53–3.27 <.0001 1.96 1.36–2.81 <.0001
Female .96 .66–1.41 .85 1.00 .70–1.43 .98
Tumor size ≥5cm 1.35 .94–1.95 .11 1.32 .93–1.87 .12
c-Rel+ 1.55 1.08–2.23 .018 1.30 .92–1.83 .14
Bcl-2+ 2.15 1.49–3.72 <.0001 1.92 1.15–2.72 <.0001
Myc+ 2.35 1.49–3.72 <.0001 2.17 1.43–3.31 <.0001
TP53 mutation 1.69 1.13–2.50 .011 1.69 1.36–2.81 .007
ABC DLBCL
B-symptoms 1.29 .79–2.12 .31 1.23 .76–1.99 .39
IPI >2 2.17 1.29–3.67 .004 1.93 1.17–3.17 .01
Female 1.25 .77–2.03 .38 1.28 .80–2.05 .31
Tumor size ≥5cm 1.19 .74–1.92 .48 1.12 .71–1.77 .63
c-Rel+ 1.69 1.06–2.68 .026 1.49 .96–2.33 .076
Bcl-2+ 1.93 1.15–3.24 .013 1.85 1.13–3.00 .014
Myc+ 2.18 1.16–4.09 .015 1.79 1.01–3.18 .047
TP53 mutation 2.19 1.20–3.99 .011 1.88 1.04–3.39 .035
DLBCL with WT-p53
B-symptoms 1.60 1.04–2.47 .033 1.55 1.03–2.35 .037
IPI >2 2.38 1.55–3.66 <.0001 2.13 1.42–3.18 <.0001
Female .98 .63–1.52 .92 .96 .64–1.46 .86
Tumor size ≥5cm 1.22 .80–1.87 .36 1.10 .73–1.65 .65
c-Rel+ 1.87 1.23–2.84 .003 1.58 1.07–2.34 .023
DLBCL with MUT-p53
B-symptoms 1.21 .56–2.62 .63 1.06 .51–2.19 .87
IPI >2 2.91 1.40–6.04 .004 2.54 1.28–5.04 .008
Female .77 .38–1.56 .47 .88 .45–1.71 .70
Tumor size ≥5cm 1.74 .84–3.62 .14 1.91 .96–3.79 .065
c-Rel+ .60 .27–1.34 .22 .62 .30–1.30 .21
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; IPI, international prog-
nostic index. Cutoffs for c-Rel+, Bcl-2+, and Myc+: 5% and 70% respectively.
suggesting that activation of c-Rel was mediated through 
the canonical pathway [2]. Genes encoding IκBα/β/ε 
(which sequester NF-κB in the cytoplasm) and IκB-
zeta (which inhibits NF-κB transcription activity) 
were significantly upregulated in either GCB- or ABC-
DLBCL (Supplementary Fig. S3M-P), resembling p65 
function [38].
Upregulation of TNFAIP3/A20 and TNIP1 (which 
inhibit MALT1, IKK3 and TRAF6 [37]) in c-Rel+ GCB-
DLBCL (Fig. 3E) may be relevant for the decrease of 
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pAKT and Myc levels coincided with c-Rel positivity 
(Fig. 3A-3C) and the lack of c-Rel prognostic impact 
[39, 40]. Upregulation of IKK2 and IκBs in c-Rel+ GCB-
DLBCL may contribute to the decreased p53 levels in 
GCB-DLBCL (Fig. 3D) [41]. In addition, decrease of 
Myc may also result from MYC repression by FOXP3 [42] 
and posttranslational regulation of Myc stability by the 
ubiquitin-proteasome system. This was suggested by the 
upregulation of FOXP3 (Fig. 3F-3G) in c-Rel+ DLBCL 
which was opposite to the decrease of Myc in c-Rel+ 
DLBCL (≥5% and 30% cutoff respectively) (Fig. 3B-
3C), and upregulation of FBXW7 (Fig. 3H), PIN1 
(P < 0.0001), and PPP2R2A (P = 0.043) (which facilitate 
Myc degradation [43]) in c-Rel+ GCB-DLBCL.
Expression of c-Rel target genes
c-Rel is known to transcriptionally regulate genes 
involved in inflammation, immune cell development and 
cell survival [4, 7]. Gene expression analysis between 
c-Rel+ and c-Rel− DLBCL showed up- or downregulation 
of FOXP3 (Fig. 3F-3G), IL1B, IL3, IL6, IL10RA, IL12B, 
IL12RB1, IL17A, STAT3, JAK1/3, RUNX1/3, CXCR4, 
PRDM1, TP63, and CDKN1A (border-line P value) 
(Supplementary Fig. S4B-O) in c-Rel+ versus c-Rel− 
DLBCL, either in the GCB or ABC subtype. c-Rel did not 
appear to correlate with transcription of apoptotic genes 
significantly (data not shown) except antiapoptotic CFLAR 
(upregulated in GCB-DLBCL, P = 0.043, Supplementary 
Fig. S4P). Gene expression of antiapoptotic BCL2L1 
(P = 0.13), MCL1 (P = 0.10), and TRAF1 (P = 0.10) also 
tended to be higher in c-Rel+ GCB-DLBCL.
Gene expression signature of c-Rel expression in 
overall-, GCB- and ABC-DLBCL
To better understand regulation and function 
of c-Rel underlying its clinical impact, genome-wide 
gene expression of c-Rel+ and c-Rel− DLBCLs were 
compared in the overall and subsets of cohorts. Distinct 
GEP signatures were shown in overall- (Fig. 3I; Table 4) 
and GCB- (Fig. 3J; Supplementary Table S1) but not in 
ABC-DLBCL. These c-Rel signatures showed similarity 
and difference with that in T-cells [44], including genes 
Figure 3: Gene and protein expression analysis correlating with c-Rel nuclear expression. A–D. c-Rel positivity correlated 
with significantly lower levels of pAKT, Myc or p53 protein expression in DLBCL or GCB-DLBCL. E–F. A20/TNFAIP3 which negatively 
regulates BCR, TNF, and NF-κB signaling, and c-Rel target gene FOXP3, were significantly upregulated in c-Rel+ GCB-DLBCL. G. Higher 
c-Rel expression levels (≥30%) correlated with significantly higher FOXP3 mRNA levels in both GCB- and ABC-DLBCL. H. FBXW7 was 
significantly upregulated in c-Rel+ GCB-DLBCL. Note: red lines indicate upregulation whereas blue lines indicated downregulation with 
significant or border-line P values. I–J. Heatmaps by gene expression profiling analysis between c-Rel+ and c-Rel− DLBCL in the overall 
and GCB-DLBCL cohorts. K. Heatmap by gene expression profiling analysis between c-Rel+ and c-Rel− DLBCL with low Bcl-2 expression 
(<70%). L. Heatmap by gene expression profiling analysis between c-Rel+ and c-Rel− DLBCL without p63 expression.
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Table 4: Gene signatures of c-Rel+ in the overall DLBCL cohort (false discovery rate < .10), and 
gene signatures of REL amplification identified in the overall (false discovery rate < .05, fold change 
>2) or GCB-DLBCL cohort (false discovery rate < .05)
Function
c-Rel+ vs. c-Rel− REL amp+ vs. REL amp−
Upregulated Downregulated Upregulated Downregulated
Mitogen, cytokine, 
growth factor, 
receptors, signal 
transduction, NF-κB 
activation
CTGF, AEBP1, 
IGFBP7, GPR124, 
RASEF, PTGFRN
PTP4A3, CCL17, 
KISS1R*, IL8*, 
CD80*, CAMKK2*
P2RX5, IL7, PRKCB
DNA replication, 
recombination, cell 
cycle
MLF1IP C10orf78 STAG3, H1F0*, NDNL2*
Gene expression, 
transcription and 
translation regulation
JUN, MED12, 
SFMBT2, NSD1
KDM5A, ZNF267, 
TCERG1
REL‡, PUS10‡, 
FYTTD1, CREM‡, 
DENND4A‡, ZNF711, 
KDM4B, PAPOLG‡, 
SSX4, MED13L*
FOXP1
Actin, cytoskeleton, 
collagen, cell 
morphology, 
adhesion, 
extracellular matrix, 
migration, muscular 
system function
TAGLN, CALD1, 
MYH11, CCDC80, 
SSH1, BGN, HSPG2, 
KIAA1109
LAMA3
CCT4, PLS3, KIF26B‡, 
ABLIM1, DYNC1I1*, 
DNAH14*
Protein sorting, 
protein and 
vesicle’s trafficking, 
transportation, 
chaperone
GGA3, COG5
SEC23B, PLDN, 
TXNDC9, TGOLN2, 
SRP72, SDCCAG1, 
NIPSNAP3A
CSMD1‡, CLCNKB, 
AHSA2‡, XPO1, 
PEX13‡
Metabolism, redox
NADSYN1, 
CKMT1A/B, 
SLC25A16, POMT2
C18orf55, YME1L1 CTPS2 ODC1, GBA2*
Tumor suppressor, 
apoptosis, autophagy MEG3 CISD2
CSMD1‡, TUSC1, 
C20orf117
Degradation RNF180, USP34
‡, 
MAGEA3, COMMD1*
Unknown function NPIP, ANO8
JRKL, DNAJC9, 
GCOM1/GRINL1A, 
NOL10
CT45A5‡, MAGEA9‡, 
BTNL9, SYT17, 
KIAA1841, 
DNAJC5B, FAM9C‡, 
CTAG1A/B‡, ZCCHC7, 
ZC3HAV1L*, 
LOC339803*, 
ACOXL*, C22orf37*, 
PRUNE2*, DUSP5P*, 
CENPBD1*, 
MAGEA5*, MEGF8*
MPEG1
*  Genes identified in the comparison of patients with and without REL amplification within GCB-DLBCL cohort only;
‡ Genes identified in both comparisons (comparisons in the overall cohort and in the GCB-DLBCL cohort).
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involved in signaling, transcription, differentiation, 
tumor suppression, metabolism, cytoskeleton, adhesion, 
extracellular matrix assembly, metastasis and angiogenesis. 
AEBP1 promoting degradation of IκBα and NF-κB 
activation, and UBA7 encoding an E1 ubiquitin-activating 
enzyme were upregulated, whereas SDCCAG1 with 
a role in nuclear export was downregulated in c-Rel+ 
DLBCL. BRD2 encoding a BET transcription factor, 
which enhances IKK activity and NF-κB activation in 
ABC-DLBCL in vitro and in vivo [45], was significantly 
upregulated in c-Rel+ GCB-DLBCL. Upregulation of 
FOXO3 in c-Rel+ GCB-DLBCL, which is negatively 
regulated by PI3K/AKT and inhibits MYC expression and 
function directly or indirectly [46], is consistent with the 
decreased pAKT and Myc levels in c-Rel+ DLBCL. MEG3, 
which encodes a long non-coding RNA that increases p53 
levels, and tumor suppressor gene RBM5 were upregulated 
in c-Rel+ DLBCL and c-Rel+ GCB-DLBCL respectively.
Functional dependence on other NF-κB subunits and 
distinctive function of c-Rel in overall-, GCB- and 
ABC-DLBCL
In order to identify the dependency and distinctive 
functions of c-Rel versus other NF-κB subunits, we 
compared the GEP of c-Rel+ and c-Rel− within p50−, p65−, 
p52−, RelB−, p50+, p65+ p52+ and RelB+ DLBCL subsets 
individually. c-Rel showed GEP signatures in p50+, 
p65+, p52− and RelB− DLBCL subsets (Supplementary 
Fig. S2M-2N; Supplementary Table S2), but not in p50−, 
p65−, p52+ or RelB+ DLBCL. These results may suggest 
that c-Rel functions mainly through the canonical pathway 
in the forms of c-Rel/p50 and c-Rel/p65 dimers. The 
results also imply that c-Rel/p65 and c-Rel/p50 dimers 
have significantly distinctive activities compared to other 
p65 or p50 dimers (mainly p50/p65 and p50/p50 dimers 
[22, 47], potentially also p65/p65 [48], p50/p52 [49], p50/
RelB dimers [22]).
c-Rel function in GCB-DLBCL did not appear to 
depend on other single NF-κB members significantly, 
because no c-Rel signatures were identified within 
p50+, p65+ p52+ or RelB+ GCB-DLBCL, whereas 16 
differentially expressed genes (DEGs) were identified 
within the RelB− GCB-DLBCL subset by a high false 
discovery rate (FDR < 0.30) threshold.
Although c-Rel nuclear expression did not show 
distinctive GEP signature in the overall ABC-DLBCL, 
within the p65+ ABC-DLBCL subset there were 64 DEGs 
between c-Rel+ and c-Rel− (FDR < 0.25), and within 
the p50+ ABC-DLBCL subset 28 DEGs (FDR < 0.30) 
(Supplementary Fig. S2O-2P; Supplementary Table S3), 
supporting the idea that c-Rel function depended on p65 
and p50 activation as suggested by the survival analysis 
(Fig. 2E-2F). On the other hand, the differential expression 
of these DEGs between c-Rel+ and c-Rel− within the 
p65+ or p50+ ABC-DLBCL groups also suggested that 
c-Rel/NF-κB dimers compared with other p65 or p50 
dimers have significantly distinct roles in regulation 
of proliferation, apoptosis, metabolism, trafficking, 
cell adhesion, migration, and angiogenesis . In c-Rel+/
p65+ (versus c-Rel−/p65+) ABC-DLBCL, SIGIRR which 
attenuates the TLR4 signaling, AEBP1, TFE3 (which 
activates CD40L expression), and HSPB1 (encoding 
Hsp27 which can either decrease IKK2 activity [50], or 
enhance proteasomal degradation of IκBα [51]), were 
upregulated; SETD6, encoding a methyltransferase which 
impedes p65 function, was downregulated. In both c-Rel+/
p65+ (versus c-Rel−/p65+) and c-Rel+/p50+ (versus c-Rel−/
p50+) ABC-DLBCL, PSMG1 which promotes assembly of 
the 20S proteasome was downregulated.
c-Rel signatures in Bcl-2− and p63− DLBCL
To understand the significant prognostic impact of 
c-Rel expression in Bcl-2− and p63− DLBCL (Fig. 2D, 2L), 
GEP analysis was also performed in Bcl-2− and p63− 
DLBCL subsets. In Bcl-2− DLBCL, c-Rel expression 
was associated with upregulation of BCL6 (required 
for GC formation), JUN, MYCBP2 (MYC binding 
protein 2, involved in Myc transcriptional activities and 
degradation of target proteins), cyclin genes CCNK and 
CCNI, LPIN1 involved in metabolism, DDR2 encoding 
a tyrosine kinase, and PSMF1, which inhibits the 
hydrolysis of protein and peptide substrates by the 20S 
proteasome (Fig. 3K). In p63− DLBCL, c-Rel expression 
was associated with upregulation of BCL6, EGR1, 
AEBP1, C7orf68, CCNG2, CCNI, ILKAP, and PSMG4 
(encoding a chaperone protein which promotes assembly 
of the 20S proteasome) and downregulation of FBXO22 
(involved in degradation of specific proteins in response 
to p53 induction) (Fig. 3L). In contrast, no genes were 
significantly differentially expressed between c-Rel+ and 
c-Rel− patients in the Bcl-2+ or p63+ DLBCL subset. To 
understand the tumor suppressor function of p63 towards 
c-Rel signaling, we further compared GEP between p63+ 
and p63− patients within the c-Rel+ DLBCL subset, and 
found that LYN was significantly downregulated in p63+ 
DLBCL, suggesting that p63 may inhibit BCR signaling 
thus attenuate c-Rel activation.
c-Rel signatures in the WT-p53 and MUT-p53 subsets 
and crosstalk between c-Rel and the p53 Pathway
c-Rel nuclear expression showed distinctive GEP 
signature only in the WT-p53 subcohort, (Supplementary 
Fig. S2L), but not in the MUT-p53 subcohort probably 
due to the heterogeneous and dominant MUT-p53 
function [36]. The c-Rel GEP signature in the WT-
p53 subcohort included oncogene JUN, CTTN which 
contributes to tumor cell invasion and metastasis, ENG 
involved in the regulation of angiogenesis, SH3GL1 with 
a role in cell cycle whose overexpression may play a role 
in leukemogenesis, LPIN1 and CKMT1A/B involved in 
metabolism regulation, and many genes involved in Golgi 
function. On the other hand, RASEF with a potential role 
as tumor suppressor, and CREBZF (a positive regulator 
of p53 [52]) were also upregulated, whereas YME1L1 
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which plays a role in mitochondrial protein metabolism 
and promotes antiapoptotic activities was downregulated. 
DEGs involved in epigenetic regulation include 
upregulatd NSD1 and downregulated KDM5A and MYSM1 
(Supplementary Table S4).
Moreover, nuclear c-Rel positivity coincided 
with significantly upregulated TP53 transcription in 
ABC-DLBCL with MUT-p53 (Fig. 4A), whereas 
significantly upregulated TP63 and p63 protein levels 
in ABC-DLBCL with WT-p53 (Fig. 4B, Supplementary 
Fig. S5A). Conversely, in ABC-DLBCL, TP53 mutations 
were associated with significantly upregulated REL 
mRNA (Supplementary Fig. S5B) and higher nuclear 
c-Rel protein levels (Fig. 4C), and p63+ ABC-DLBCL had 
trend for elevated nuclear c-Rel protein levels (P = 0.06, 
Fig. 4D). In GCB-DLBCL, expression of MUT-p53 and 
p63 was associated with higher REL mRNA (P = 0.082 and 
P = 0.0016 respectively, Supplementary Fig. S5C-S5D). 
 To exclude REL amplification as a potential compounding 
factor, we performed the same analyses in patients without 
Figure 4: Crosstalk between c-Rel and the p53 pathway. A. In ABC-DLBCL with MUT-p53, c-Rel nuclear expression was 
associated with significantly higher TP53 mRNA. B. In ABC-DLBCL with WT-p53, c-Rel nuclear expression was associated with 
significantly higher TP63 mRNA. C. In ABC-DLBCL, TP53 mutations were associated with significantly higher c-Rel nuclear expression 
levels. D. In ABC-DLBCL, p63 expression coincided with higher c-Rel nuclear expression levels. E. c-Rel nuclear expression significantly 
correlated with CDKN1A/p21 downregulation in GCB-DLBCL with MUT-p53, but not in GCB-DLBCL with WT-p53. F. TP53 mutations 
significantly correlated with CDKN1A/p21 downregulation in GCB-DLBCL with c-Rel nuclear expression, but not in GCB-DLBCL without 
c-Rel nuclear expression. G. c-Rel nuclear expression significantly correlated with BIRC5 upregulation in ABC-DLBCL with MUT-p53, 
but not in ABC-DLBCL with WT-p53. H. In ABC-DLBCL with c-Rel nuclear expression, TP53 mutations appeared to be associated with 
higher BIRC5 transcription (marginal P value); in contrast without c-Rel nuclear expression, p53 mutant group correlated with significantly 
higher BIRC5 transcription in GCB-DLBCL, whereas appeared to have slightly lower BIRC5 transcription in ABC-DLBCL. Note: red 
lines indicate upregulation with significant or border-line P values whereas blue lines indicated downregulation. I. Hypothetical models of 
crosstalk between c-Rel, p53, and p63 in GCB- and ABC-DLBCL with WT- or MUT-p53 suggested by our data.
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REL amplification or polysomies, and found that only the 
correlation between TP53 mutations (but not p63+) and 
upregulated REL mRNA (but not the c-Rel protein) in 
ABC-DLBCL was affected.
c-Rel+ DLBCL with MUT-p53 which 
was associated with significantly worse survival 
(Fig. 2H-2I), also correlated with decreased pAKT and 
Myc expression (Supplementary Fig. S2I-2J), as seen 
in c-Rel+ DLBCL with WT-p53 which did not show 
worse survival by univariate survival analysis (Fig. 2G). 
Therefore to confer worse prognostic impact, c-Rel 
must have used other oncogenic pathways. We analyzed 
expression of c-Rel and p53 target genes, which appeared 
to suggest that MUT-p53 and c-Rel gained functions in 
downregulating p21 in GCB-DLBCL (Fig. 4E-4F), and 
upregulating BIRC5 (encoding antiapoptotic survivin) 
in ABC-DLBCL (Fig. 4G-4H). Our data also suggested 
possible lost-of-function of c-Rel in the presence of 
MUT-p53 in upregulating TP63 in ABC-DLBCL, 
and gain-of-function in inducing NFKB1, TANK, and 
BCL2L11 in GCB-DLBCL, AURKB, RELA, and BAD 
in ABC-DLBCL, as well as downregulating TRAF2 
in GCB-DLBCL and BCL2L11 in ABC-DLBCL 
(Supplementary Fig. S5–S6).
A hypothetical model for the reciprocal induction 
of REL, TP53 and TP63 and other biology suggested by 
GEP analysis in GCB- and ABC-DLBCL with WT- or 
MUT-p53 is depicted in Fig. 4I.
Clinical relevance and gene expression signature 
of REL amplification in DLBCL
REL amplification detected by FISH (Fig. 5A-5B) 
was found predominantly in GCB-DLBCL (only two cases 
of ABC-DLBCL), with a frequency of 4.2% of overall 
DLBCL, or 7.1% of GCB-DLBCL. REL amplification 
correlated with significantly higher REL mRNA levels 
(Fig. 5C-5D), but not with c-Rel nuclear expression 
(Fig. 5E), clinical parameters (Table 5) or patient survival 
either in overall- or GCB-DLBCL (Fig. 5F-5G), suggesting 
the importance of posttranslational regulations for c-Rel 
activation and function.
REL amplification showed distinct GEP signatures 
in either overall or GCB-DLBCL (Table 4; Fig. 5H). 
Except CCT4 gene which was also mapped to 2p as REL, 
these DEGs were not overlapping with those associated 
with 2p gain in chronic lymphocytic leukemia [53]. 
USP34 (mapped to 2p; encoding a deubiquitinase which 
negatively regulates NF-κB activation), COMMD1 
(mapped to 2p; COMMD1 can enhance p65 nuclear 
degradation), RNF180 (E3 ubiquitin-protein ligase), and 
XPO1 (mapped to 2p; encoding CRM1 which enhances 
p65 nuclear export) were upregulated. Upregulated 
MAGEA3, which stimulates p53 ubiquitination by 
enhancing TRIM28 ubiquitin ligase activity, could 
negatively regulate p53 levels. However, proapoptotic 
PUS10 (mapped to 2p) and the tumor suppressor genes 
CSMD1, KISS1R, NDNL2, TUSC1 and DENND4A 
(repressing MYC transcription) were upregulated, which 
may also explain the lack of prognostic significance of 
REL amplification.
DISCUSSION
c-Rel is a unique NF-κB member important for 
lymphocyte development, proliferation and survival 
[4, 17], however, the clinical relevance of c-Rel activities 
in DLBCL has not been well studied with inconsistent 
results. In a cohort of 460 DLBCL patients, we found 
c-Rel nuclear expression positive in 26% of DLBCL 
patients at lower levels than p65 and p50, and associated 
with extranodal DLBCL. c-Rel nuclear expression 
conferred adverse impact in ABC-DLBCL with context-
dependent prognostic significance. Remarkably, c-Rel 
nuclear expression had significantly synergistic effects 
with TP53 mutations. Although c-Rel positivity did 
not show prognostic significance in DLBCL with 
WT-p53, multivariate analysis indicated that c-Rel 
was an independent adverse prognostic factor after 
adjusting clinical parameters. Compared with studies 
in the literature, the positivity frequency in our study is 
lower than the 65% and 64% by two previous reports 
(0% and 30% cutoff respectively) [34, 35], and higher 
than the 18% by another study using a >50% cutoff 
[54]; the prognostic significance of c-Rel nuclear 
expression in MUT-p53 and various ABC-DLBCL 
subsets demonstrated in our cohort have not been 
reported previously. Moreover, we also found that REL 
amplifications in 4.2% of DLBCL had no correlation 
with nuclear accumulation of c-Rel (consistent with 
a previous study [33]) or prognosis (no earlier studies 
have been reported). In fact, if polysomy cases (46% are 
of ABC subtype) are also included into REL amplified 
cases which resulted in a frequency of 12% for REL 
amplification in DLBCL, REL amplification correlated 
with better patient survival in ABC- but not in GCB-
DLBCL. We further found that several genes, which 
are also mapped to 2p, and involved in deubiquitination 
of IκB, degradation, nuclear export of NF-κB, or 
proapoptosis, were highly expressed in REL amplified 
cases likely due to co-amplification.
The lack of prognostic impact of c-Rel nuclear 
expression in GCB-DLBCL probably results from 
the decrease in Myc, AKT and p53 expression, and 
the complicated interaction and relationships with other 
NF-κB subunits. Upregulation of FOXP3 [42], FOXO3 
[46], A20 [39, 40], IKK2 and IκBs [41, 49] in c-Rel+ GCB-
DLBCL may be relevant for the reductions as well as the 
phosphorylation-dependent ubiquitin-proteasome system 
which mediates c-Rel activation and degradation of Myc 
and p53 [43, 55]. Decreased p53 and Myc levels in c-Rel+ 
GCB-DLBCL may be necessary for GC reaction [56] 
due to the proapoptotic function of p53 and Myc [22]. 
In addition, that c-Rel target FOXP3 in turn represses c-Rel 
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activation and inhibits c-Rel function shown by an earlier 
study [57] may also explain the lack of prognostic effect 
of c-Rel expression in GCB-DLBCL. In contrast, in ABC-
DLBCL, elevated IKKs and other activated signaling (such 
as BCR) may have increased Myc protein stability [40]; and 
overexpressed Myc in turn inhibits FOXO3 function [58].
In agreement with a recent study that demonstrated 
c-Rel is required for the GC maintenance [17], our data 
showed distinctive c-Rel signatures in GCB- DLBCL but 
not in the overall ABC-DLBCL cohort (Fig. 3J); BCL6, 
essential for GC maintenance, was upregulated in both 
c-Rel+/Bcl-2− and c-Rel+/p63− DLBCL (Fig. 3K-3L). c-Rel 
may have different functions by forming different NF-κB 
dimers. In ABC-DLBCL, c-Rel function depends on p50 
and p65 suggested by GEP (Supplementary Fig. S2O-2P) 
and survival analysis (Fig. 2E-2F). Moreover, in Bcl-2− 
DLBCL especially Bcl-2− ABC-DLBCL, c-Rel+ correlated 
with significantly poorer survival (Fig. 2D), supporting the 
idea that c-Rel exerted its oncogenic function via Bcl-2-
independent pathways [17].
Figure 5: REL amplification analysis in DBLCL. A–B. Representative DLBCL cases positive or negative for REL amplification 
by fluorescence in situ hybridization analysis. C–D. REL amplification correlated with significantly higher REL mRNA levels. E. REL 
amplification did not correlate with c-Rel nuclear expression levels. F–G. REL amplification did not correlate with patient survival in 
overall- or GCB-DLBCL. H. Heatmap of gene expression profiling analysis for REL amplification in GCB-DLBCL.
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Table 5: Clinicopathologic characteristics of 407 de novo DLBCL patients tested for REL 
amplification status
DLBCL GCB-DLBCL
REL amp+ REL amp− REL amp+ REL amp−
Variables N (%) N (%) P N (%) N (%) P
Patients 17 (100) 390 (100) 15 (100) 198 (100)
Gender
Male 7 (41) 239 (61) .097 6 (40) 120 (61) .17
Female 10 (59) 151 (39) 9 (60) 78 (39)
Age (yr)
<60 8 (47) 170 (44) .77 8 (53) 103 (52) 1.0
≥60 9 (53) 220 (56) 7 (47) 95 (48)
Stage
I-II 10 (59) 180 (48) .37 9 (60) 107 (56) .75
III-IV 7 (41) 198 (52) 6 (40) 85 (44)
B-symptoms
No 13 (77) 242 (65) .35 12 (80) 130 (70) .42
Yes 4 (23) 128 (35) 3 (20) 55 (30)
Serum LDH
Normal 8 (47) 144 (41) .60 7 (47) 77 (43) .81
Elevated 9 (53) 210 (59) 8 (53) 100 (57)
# of extranodal sites
0–1 16 (94) 287 (76) .085 14 (93) 148 (78) .17
≥2 1 (6) 90 (24) 1 (6) 41 (22)
Performance score
0–1 17 (100) 289 (84) .068 15 (100) 145 (85) .11
≥2 0 (0) 59 (16) 0 (0) 25 (15)
Size of largest tumor
<5cm 8 (57) 176 (59) .91 7 (54) 90 (61) .62
≥5cm 6 (43) 124 (41) 6 (46) 58 (39)
IPI risk group
0–2 14 (82) 239 (89) .11 13 (87) 130 (68) .14
3–5 3 (18) 139 (11) 2 (13) 62 (32)
Therapy response
CR 14 (82) 295 (76) .77 12 (80) 146 (74) 1.0
PR 0 51 0 24
SD 0 16 0 10
(Continued )
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DLBCL GCB-DLBCL
REL amp+ REL amp− REL amp+ REL amp−
Variables N (%) N (%) P N (%) N (%) P
PD 3 28 3 18
Cell-of-origin
ABC 2 (12) 190 (49) .0024 0 (0) 0 (0) -
GCB 15 (88) 198 (51) 15 (100) 198 (100)
Primary origin
Nodal 9 (53) 253 (66) .30 7 (53) 131 (68) .10
Extranodal 8 (47) 130 (34) 8 (47) 63 (32)
Ki-67
<70% 5 (29) 147 (38) .61 5 (33) 82 (42) .59
≥70% 12 (71) 238 (62) 10 (68) 112 (58)
TP53 mutation
MUT TP53 6 (35) 79 (22) .20 5 (33) 46 (25) .49
WT TP53 11 (65) 280 (78) 10 (67) 136 (25)
p53 expression
+ 8 (47) 126 (36) .44 7 (47) 66 (37) .58
− 9 (53) 227 (64) 8 (53) 113 (63)
MYC translocation
+ 1 (8) 31 (12) 1.0 1 (10) 21 (17) 1.0
− 11 (92) 228 (88) 9 (90) 102 (83)
BCL2 translocation
+ 5 (29) 54 (16) .18 5 (33) 45 (29) .77
− 12 (71) 273 (84) 10 (67) 112 (71)
BCL6 translocation
+ 5 (33) 88 (32) .91 5 (38) 33 (24) .24
− 10 (67) 187 (68) 8 (62) 106 (76)
Bcl-2 expression
+ 5 (29) 191 (50) .13 4 (27) 80 (41) .41
− 12 (71) 194 (50) 11 (73) 115 (59)
Myc expression
+ 5 (29) 117 (30.5) 1.0 4 (27) 55 (29) 1.0
− 12 (71) 266 (69.5) 11 (73) 137 (71)
pAKT
+ 1 (6) 75 (20) .21 1 (6) 37 (19) .31
− 16 (94) 307 (80) 14 (94) 156 (81)
(Continued )
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We attempted to understand the dependence and 
differences between c-Rel and other NF-κB members. 
Coexpression in patients and coimmunoprecipitation 
analysis in primary DLBCL cells suggest c-Rel can form 
complexes with all NF-κB subunits. However, by GEP and 
survival analyses dissecting c-Rel function and prognostic 
impact with and without concurrent activation of other NF-
κB subunits, our results suggested that the oncogenic c-Rel 
dimers with clinical significance are likely predominated 
of c-Rel/p65 and c-Rel/p50 in ABC-DLBCL, and 
potentially c-Rel/c-Rel dimers in GCB-DLBCL, which 
are all activated via the canonical pathway [4, 17, 68, 69].
Our data suggested crosstalk exist between c-Rel and 
the p53 pathway, including MUT-TP53 induction at the 
transcriptional level in c-Rel+ ABC-DLBCL, the gain or 
loss of correlation with expression levels of genes involved 
in cell cycle (p21, AURKB), apoptosis (BIRC5, BCL2L11), 
TNF pathways (TRAF2, TANK), and tumor suppressor 
TP63. Concurrent c-Rel positivity and TP53 mutation 
correlated with significantly worse patient survival. 
This may excel result from formation of different c-Rel/
NF-κB dimers, functional alterations, posttranslational 
modification [59], or increased REL mutations in patients 
with MUT-p53 [60]. In contrast, WT-p53 and p63 may 
excel tumor suppressor function towards c-Rel signaling by 
cell cycle arrest, proapoptosis and BCR signaling inhibition 
therefore abolished the prognostic effect of c-Rel activation.
In summary, c-Rel nuclear expression but not REL 
amplification has an adverse prognostic effect in DLBCL 
which synergized with TP53 mutations. c-Rel has distinctive 
and overlapping functions compared with other NF-κB 
subunits, and c-Rel/p65 and c-Rel/p50 dimers may be 
relevant for the oncogenic role of c-Rel in DLBCL. The 
biology revealed by c-Rel GEP signatures from this study 
has gained insight into the NF-κB pathways providing 
important information for further functional study, and 
suggest that therapeutic approaches targeting BCR, cell 
cycle, cytokine, and the p53 pathway, as well as BET 
inhibitors, but not proteasome inhibitors, may have clinical 
benefits in c-Rel+ DLBCL patients.
PATIENTS AND METHODS
Patients
This study included 460 patients with de novo DLBCL 
treated with standard R-CHOP immunochemotherapy 
consisting of rituximab plus cyclophosphamide, 
DLBCL GCB-DLBCL
REL amp+ REL amp− REL amp+ REL amp−
Variables N (%) N (%) P N (%) N (%) P
p16
+ 10 (67) 95 (29) .0038 9 (69) 58 (35) .017
− 5 (87) 230 (71) 4 (31) 110 (65)
Nuclear p50
+ 6 (40) 188 (52.7) .43 6 (46) 78 (42) .78
− 9 (60) 169 (47.3) 7 (54) 106 (58)
Nuclear p52
+ 5 (33.3) 99 (27) .56 4 (31) 56 (30) 1.0
− 10 (66.7) 268 (73) 9 (69) 129 (70)
Nuclear p65
+ 8 (50) 223 (60.6) .44 7 (50) 113 (61) .41
− 8 (50) 145 (39.4) 7 (50) 72 (39)
Nuclear RelB
+ 0 (0) 58 (15.9) .14 0 (0) 27 (15) .22
− 15 (100) 306 (84.1) 13 (100) 159 (85)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell like; ABC, activated B-cell like; LDH, lactate 
dehydrogenase; IPI, international prognostic index; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease.
Note: Immunohistochemistry cutoff for biomarkers: c-Rel, p50, p65, RelB, 5%; p53, ≥20%; Myc, 70%; Bcl-2, ≥70%; PAKT, 
≥70%; p16, >10%.
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hydroxydaunomycin (doxorubicin), oncovin (vincristine), 
and prednisone. The diagnosis, review process, and 
cell-of-origin classification according to GEP or the 
immunohistochemical algorithms of Visco-Young and/or 
Choi have been described previously [36, 61]. Patients were 
excluded if they had HIV infection, primary cutaneous or 
nervous system DLBCL, primary mediastinal large B-cell 
lymphoma, or a history of low-grade B-cell lymphoma with 
transformation to DLBCL. This study was conducted in 
accordance with the Declaration of Helsinki, and informed 
consent was obtained from all patients whose tumor 
samples were used. The study protocol and material transfer 
agreement were approved by the institutional review boards 
of all participating centers. The overall study was approved 
by the Institutional Review Board of The University of 
Texas MD Anderson Cancer Center.
Tissue microarray (TMA) and 
immunohistochemical assay
Immunohistochemical analysis for c-Rel, p50, 
p52, p65, RelB, p53, p63, Myc, Bcl-2, pSTAT3, pAKT, 
MDM2, and Ki-67 was performed on the TMA prepared 
with formalin-fixed, paraffin-embedded (FFPE) tissue 
blocks from all of the 460 DLBCL patients using methods 
previously described [36, 61, 67]. The results were 
analyzed independently by a group of hematopathologists 
(LL, CYO, AT, KHY), and disagreements were resolved by 
joint review with use of a multi-head microscope [70, 71].
TP53 mutation and fluorescence in situ 
hybridization (FISH) analysis
Genomic DNAs extracted from FFPE tissues 
were used for TP53 exon sequencing analysis with use 
of the AmpliChip (Roche Molecular Systems) [36]. 
FISH analysis for REL amplification used a customer 
developed dual-color mix (Agilent Technologies, 
G100258R-8) consisting of a 2p16.1 (REL-locus) probe 
labeled with Spectrum Orange and a reference probe 
(chromosome 2 centromere) labeled with Spectrum 
Green. Dual-color FISH was performed on 4 micron 
sections of the TMAs. Fluorescence signals were scored 
by counting the number of single-copy genes and 
reference probe signals in 200 well-defined nuclei. High-
level amplification was defined as the presence of either 6 
gene signals or tight clusters of at least five gene signals 
per cell. Low level gains were considered when the ratio 
between REL and CEP2 signals exceeded 2. Cases were 
considered polysomic for chromosome 2e if the number 
of tumor cell nuclei with three or more signals exceeded 
the mean +3 s.d. of polysomic nuclei in the reference 
cases (i.e. 15%). Five tonsils were used as references.
Probes and methods of FISH analysis for MYC, 
BCL2, and BCL6 translocation have been described 
previously [62].
Gene expression profiling
Total RNAs were extracted from FFPE tissues and 
used for GEP by Affymetrix GeneChips array as described 
previously [36, 61]. GEP was achieved in 453 DLBCL 
patients. The CEL files are deposited in the National 
Center for Biotechnology Information Gene Expression 
Omnibus repository (GSE#31312).61 The microarray 
data were quantified and normalized by the frozen robust 
multiarray analysis (RMA) algorithm. The DEGs were 
identified by using multiple t-tests. Pathway analysis 
for the DEGs was performed with use of the Ingenuity 
Pathway Analysis software program (http://www.qiagen.
com/ingenuity).
Cell culture and coimmunoprecipitation
Human-derived DLBCL cell lines (MS, DB, LR, LP) 
were established from tissue biopsy or effusion specimens 
from patients as described previously [63, 64]. The cells 
were cultured in RPMI medium (Gibco, Rockville, MD) 
containing 15% fetal calf serum (FCS; Hyclone, Logan, 
UT). Coimmunoprecipitation was carried out as described 
previously [65, 66].
Statistical analysis
The clinical and pathologic features at the time of 
presentation were compared between various DLBCL 
subgroups by using the Chi-square test. Correlation 
between expression of different genes or proteins was 
evaluated by the Spearman rank correlation method and 
unpaired t tests. Overall survival was calculated from the 
date of diagnosis to the date of last follow-up or death. 
Progression-free survival was defined as the time period 
from the date of diagnosis to the date of progression or 
death. OS and PFS curves of the various groups were 
analyzed by GraphPad Prism 6 (GraphPad Software, 
San Diego, CA) using the Kaplan-Meier method, and 
differences were compared with use of the log-rank 
(Mantel-Cox) test. Multivariate analysis was conducted 
by using the Cox proportional hazards regression model 
with the SPSS software (version 19.0; IBM Corporation, 
Armonk, NY). Any difference with a P value of < 0.05 
was considered statistically significant.
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